General Announcement::IX BIOPHARMA REPORTS POSITIVE RESULTS FROM WAFERMINE PHASE 2 MULTI-DOSE CLINICAL EFFICACY TRIAL

Issuer & Securities

Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
05-Sep-2018 17:24:30
Status
New
Announcement Sub Title
IX BIOPHARMA REPORTS POSITIVE RESULTS FROM WAFERMINE PHASE 2 MULTI-DOSE CLINICAL EFFICACY TRIAL
Announcement Reference
SG180905OTHRDH88
Submitted By (Co./ Ind. Name)
Lee Wei Hsiung
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please refer to the attachments.

Attachments

Press Release_iX Biopharma_KET010 Top-Line Results .pdf
KET010 Top-line Results.pdf
Total size =1219K